المؤلفون: Zenon Konteatis (2236249), Jeremy Travins (4810641), Stefan Gross (673951), Katya Marjon (10571777), Amelia Barnett (10571780), Everton Mandley (10571783), Brandon Nicolay (8213556), Raj Nagaraja (8413410), Yue Chen (73753), Yabo Sun (10571786), Zhixiao Liu (3719695), Jie Yu (150626), Zhixiong Ye (1370289), Fan Jiang (144211), Wentao Wei (2135263), Cheng Fang (611972), Yi Gao (112914), Peter Kalev (10571789), Marc L. Hyer (10571792), Byron DeLaBarre (673950), Lei Jin (120473), Anil K. Padyana (1833913), Lenny Dang (2035819), Joshua Murtie (4471198), Scott A. Biller (2035810), Zhihua Sui (27883), Kevin M. Marks (1277097)

مصطلحات موضوعية: Biochemistry, Cell Biology, Genetics, Pharmacology, Biotechnology, Cancer, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, Homozygous MTAP Deletion, allosteric MAT 2A inhibitors, adenosyl methionine, small-molecule inhibitors, cancer cells, block proliferation, Previous attempts, xenograft tumors, iterative structure-guided design, enzyme methionine adenosyltransferase 2, methylthioadenosine phosphorylase, SAM levels, MAT 2A, Fragment screening, bioavailable MAT 2A inhibitors, AG -270, target MAT 2A, MAT 2A inhibitors, CDKN 2A, First-in-Class Oral MAT 2A Inhibitor, NCT, tissue culture

Relation: https://figshare.com/articles/journal_contribution/Discovery_of_AG-270_a_First-in-Class_Oral_MAT2A_Inhibitor_for_the_Treatment_of_Tumors_with_Homozygous_i_MTAP_i_Deletion/14387567

الاتاحة: https://doi.org/10.1021/acs.jmedchem.0c01895.s001

المؤلفون: Zenon Konteatis (2236249), Jeremy Travins (4810641), Stefan Gross (673951), Katya Marjon (10571777), Amelia Barnett (10571780), Everton Mandley (10571783), Brandon Nicolay (8213556), Raj Nagaraja (8413410), Yue Chen (73753), Yabo Sun (10571786), Zhixiao Liu (3719695), Jie Yu (150626), Zhixiong Ye (1370289), Fan Jiang (144211), Wentao Wei (2135263), Cheng Fang (611972), Yi Gao (112914), Peter Kalev (10571789), Marc L. Hyer (10571792), Byron DeLaBarre (673950), Lei Jin (120473), Anil K. Padyana (1833913), Lenny Dang (2035819), Joshua Murtie (4471198), Scott A. Biller (2035810), Zhihua Sui (27883), Kevin M. Marks (1277097)

مصطلحات موضوعية: Biochemistry, Cell Biology, Genetics, Pharmacology, Biotechnology, Cancer, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, Homozygous MTAP Deletion, allosteric MAT 2A inhibitors, adenosyl methionine, small-molecule inhibitors, cancer cells, block proliferation, Previous attempts, xenograft tumors, iterative structure-guided design, enzyme methionine adenosyltransferase 2, methylthioadenosine phosphorylase, SAM levels, MAT 2A, Fragment screening, bioavailable MAT 2A inhibitors, AG -270, target MAT 2A, MAT 2A inhibitors, CDKN 2A, First-in-Class Oral MAT 2A Inhibitor, NCT, tissue culture

Relation: https://figshare.com/articles/dataset/Discovery_of_AG-270_a_First-in-Class_Oral_MAT2A_Inhibitor_for_the_Treatment_of_Tumors_with_Homozygous_i_MTAP_i_Deletion/14387570

الاتاحة: https://doi.org/10.1021/acs.jmedchem.0c01895.s002